Columbia-NYU-Takeda Alliance
Request for Proposals

Columbia University, New York University, and Takeda Pharmaceuticals have formed a collaborative research alliance to initiate and advance gastroenterology (GI) research programs with high potential to impact the development of new therapeutics for patients with GI disorders. Takeda is a global, value-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda has its GI research laboratories in San Diego, California, and Cambridge Massachusetts. Our strategic collaboration is aimed at leveraging both the research & development capabilities and funding opportunities of Takeda to bridge the translational and commercial gaps of the Universities’ early stage technologies. Takeda is seeking projects that are aligned to the GI Drug Discovery Unit’s discovery and translation strategies, and also forward-looking high-risk innovative concepts.

The objective of this collaboration is to advance sponsored research at the institutional level based on Request for Proposals mechanism. The award decisions will be made by a Joint Research Committee composed of Columbia, NYU, and Takeda representatives.

The application process and funding framework is as follows:

- **Letter of Intent (LOI)**
  A non-confidential level LOI submitted by July 27th, 2020. Submissions will be collected [here](#) (all information will be encrypted and held confidential). Selected applicants will be invited to submit full proposals. Please speak with your licensing manager prior to submission.

- **Funding**
  A minimum of $50,000 in direct costs for a ~1 year Pilot Project – to be determined based on a project need basis.

Please see information booklet for further information, and below for strategic areas of interest.

**Application Timeline:**

<table>
<thead>
<tr>
<th>Event</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Letter of Intent submissions open</td>
<td>June 29th, 2020</td>
</tr>
<tr>
<td>Letter of Intent submissions close</td>
<td>July 27th, 2020</td>
</tr>
<tr>
<td>Notification of selected investigators to submit Full Proposal</td>
<td>early September</td>
</tr>
<tr>
<td>Full Proposal submission close</td>
<td>early October</td>
</tr>
<tr>
<td>Award notification (subject to mutually acceptable project plan &amp; budget)</td>
<td>early November</td>
</tr>
<tr>
<td>Project launch</td>
<td>~November 2020 (or when possible due to COVID-19 restrictions and delays)</td>
</tr>
</tbody>
</table>

**For More Information, please contact:**

Columbia University: Columbia Technology Ventures – Lab to Market [L2M@ctv.columbia.edu](mailto:L2M@ctv.columbia.edu)
Takeda: Adna Halilovic - Alliance Manager [adna.halilovic@takeda.com](mailto:adna.halilovic@takeda.com)
The GI Drug Discovery Unit is focused on a subset of target areas

**Gut Inflammation**
- IBD (Crohn’s, UC), Celiac
- Barrier integrity and mucosal healing
- Microbiome therapeutics (small/large molecules, consortia)

**Liver Disease**
- Advanced/late-stage liver disease (F3, F4 NASH), anti-fibrosis drivers
- Hepatocyte rejuvenation, regeneration, replacement
- Rare and genetic linked diseases

**Motility Disorders**
- Gastroparesis, nausea and vomiting indications
- Enteric neuropathies: Hirschsprung disease and esophageal achalasia (opportunities for cell therapy)
- Fecal incontinence

**Translational & Clinical**
- Clinically meaningful targets, biomarkers, models, assays, endpoints
- Causal validation of targets, therapeutic modulation that recapitulates human biology
- Patient progression and disease outcome predictions
- Patient identification and stratification strategies

**Other areas of interest**
- Cell and gene therapy
- Access to patient samples and/or patient cohorts
- Drug delivery with specificity and selectivity